Comparative evaluation of the effects of treatment with tocilizumab and TNF-α inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients
Open accessThe DOI matches its Crossref record; the references it cites are not checked yet.
Abstract
INTRODUCTION: Anemia of inflammation (AI) is a common complication of rheumatoid arthritis (RA) and has a negative impact on RA symptoms and quality of life. Upregulation of hepcidin by inflammatory cytokines has been implicated in AI. In this study, we evaluated and compared the effects of IL-6 and TNF-α blocking therapies on anemia, disease activity, and iron-related parameters including serum hepcidin in RA patients. METHODS: Patients (n = 93) were treated with an anti-IL-6 receptor antibody (tocilizumab) or TNF-α inhibitors for 16 weeks. Major disease activity indicators and iron-related parameters including serum hepcidin-25 were monitored before and 2, 4, 8, and 16 weeks after the initiation of treatment. Effects of tocilizumab and infliximab (anti-TNF-α antibody) on cytokine-induced hepcidin expression in hepatoma cells were analyzed by quantitative real-time PCR. RESULTS: Anemia at base line was present in 66% of patients. Baseline serum hepcidin-25 levels were correlated positively with serum ferritin, C-reactive protein (CRP), vascular endothelial growth factor (VEGF) levels and Disease Activity Score 28 (DAS28). Significant improvements in anemia and disease activity, and reductions in serum hepcidin-25 levels were observed within 2 weeks in both groups, and these effects were more pronounced in the tocilizumab group than in the TNF-α inhibitors group. Serum hepcidin-25 reduction by the TNF-α inhibitor therapy was accompanied by a decrease in serum IL-6, suggesting that the effect of TNF-α on the induction of hepcidin-25 was indirect. In in vitro experiments, stimulation with the cytokine combination of IL-6+TNF-α induced weaker hepcidin expression than did with IL-6 alone, and this induction was completely suppressed by tocilizumab but not by infliximab. CONCLUSIONS: Hepcidin-mediated iron metabolism may contribute to the pathogenesis of RA-related anemia. In our cohort, tocilizumab was more effective than TNF-α inhibitors for improving anemia and normalizing iron metabolism in RA patients by inhibiting hepcidin production.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Tocilizumab administration also lowered hepcidin and improved anemia in rheumatoid arthritis patients (Isaacs et al., 2013; Song et al., 2013) and in a monkey arthritis model (Hashizume et al., 2010).”
From Pharmacological Targeting of the Hepcidin/Ferroportin Axis (2016) · cites this paper as Song et al., 2013
In the citing paper
“Similar results were obtained when rheumatoid arthritis patients were treated with antibodies against TNFα (golimumab or infliximab), possibly as an indirect result of concomitant suppression of IL-6 (Doyle et al., 2013; Song et al., 2013).”
From Pharmacological Targeting of the Hepcidin/Ferroportin Axis (2016) · cites this paper as Song et al., 2013
In the citing paper
“IL-6 is essential for the up-regulation of HAMP upon inflammation and IL-6 blockade for the treatment of rheumatoid arthritis lowers both disease activity and circulating HAMP levels [46, 47].”
From Iron deficiency or anemia of inflammation?: Differential diagnosis and mechanisms of anemia of inflammation (2016) · cites this paper as [47]
In the citing paper
“IL-6 is essential for the up-regulation of HAMP upon inflammation and IL-6 blockade for the treatment of rheumatoid arthritis lowers both disease activity and circulating HAMP levels [46, 47].”
From Iron deficiency or anemia of inflammation?: Differential diagnosis and mechanisms of anemia of inflammation (2016) · cites this paper as [47]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
The citation lists are queued
They are fetched later and appear here then.
References 33 · Cited by 143
Metadata
- Authors
- Song, S.-N. J., Iwahashi, M., Tomosugi, N., Uno, K., Yamana, J., Yamana, S., Isobe, T., Ito, H., Kawabata, H., & Yoshizaki, K.
- Affiliations
- The University of Osaka (JP)
- Higashihiroshima Medical Center (JP)
- Kanazawa Medical University (JP)
- Louis Pasteur Center for Medical Research (JP)
- Kyoto University (JP)
- Corresponding author
- Yoshizaki, Kazuyuki
- Venue
- Arthritis Research & Therapy
- Published
- 2013-10-02
- Volume
- 15
- Issue
- 5
- Pages
- R141-R141
- ISSN
- 1478-6354 (ISSN-L)
- PMC
- PMC3978580
- OpenAlex
- W2163447382
- Cited by
- 143
- References
- 33
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 10 · 2023: 12 · 2022: 12 · 2021: 15 · 2020: 12 · 2019: 14 · 2018: 11 · 2017: 17 · 2016: 11 · 2015: 8 · 2014: 9
- FWCI
- 6.69
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/2.0/ (tdm)
- creativecommons.org/licenses/by/2.0/ (vor)
- Locations
- Arthritis Research & Therapy (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Ministry of Education, Culture, Sports, Science and Technology
- Japan Society for the Promotion of Science (25460784)
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Keywords
- rheumatoid arthritis, anemia of chronic disease, hepcidin, tocilizumab, TNF-alpha inhibitors, infliximab, IL-6 receptor inhibition, iron metabolism, disease activity, serum ferritin, C-reactive protein, vascular endothelial growth factor, hepatoma cells
- MeSH terms
- Infliximab, Adult, Aged, Anemia, Antibodies, Monoclonal, Arthritis, Rheumatoid, C-Reactive Protein, Female, Ferritins, Humans, Male, Middle Aged, Time Factors, Tumor Necrosis Factor-alpha, Interleukin-6, Gene Expression, Antirheumatic Agents, Reverse Transcriptase Polymerase Chain Reaction, U937 Cells, Vascular Endothelial Growth Factor A, Cell Line, Tumor, Antibodies, Monoclonal, Humanized, Hepcidins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparative evaluation of the effects of treatment with tocilizumab and TNF-α inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients. https://app.cochat.ai/papers/10.1186/ar4323
- The paper
- Song, S.-N. J., Iwahashi, M., Tomosugi, N., Uno, K., Yamana, J., Yamana, S., Isobe, T., Ito, H., Kawabata, H., & Yoshizaki, K. (2013). Comparative evaluation of the effects of treatment with tocilizumab and TNF-α inhibitors on serum hepcidin, anemia response and disease activity in rheumatoid arthritis patients. Arthritis Research & Therapy. https://doi.org/10.1186/ar4323
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.